First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.
- DOI
- 10.1136/jitc-2024-010565
- Published
- 2025 Jan 11
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2024-010565,
title = {First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.},
author = {Lakhani NJ and Stewart D and Richardson DL and Dockery LE and Van Le L and Call J and Rangwala F and Wang G and Ma B and Metenou S and Huguet J and Offman E and Pandite L and Hamilton E},
year = {2025},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2024-010565},
url = {https://doi.org/10.1136/jitc-2024-010565}
}RIS
TY - JOUR TI - First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. AU - Lakhani NJ AU - Stewart D AU - Richardson DL AU - Dockery LE AU - Van Le L AU - Call J AU - Rangwala F AU - Wang G AU - Ma B AU - Metenou S AU - Huguet J AU - Offman E AU - Pandite L AU - Hamilton E PY - 2025 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2024-010565 UR - https://doi.org/10.1136/jitc-2024-010565 ER -
APA
NJ, L., D, S., DL, R., LE, D., L, V. L., J, C., F, R., G, W., B, M., S, M., J, H., E, O., L, P., & E, H. (2025). First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2024-010565
Source records
- pubmed · retrieved 2026-09-25T10:26:46.437Z
- europe-pmc · retrieved 2026-09-25T10:26:46.410Z
- doaj · retrieved 2026-09-25T10:26:46.394Z